Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/19/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. NEST:IN
10. AA

Go back to Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals

BMO Capital Remains Bullish on Valeant Pharma (VRX) Following Announced Acquisition of 'Female Viagra' Maker Sprout Pharma

August 20, 2015 11:29 AM EDT

BMO Capital reiterated an Outperform rating and $285 price target on Valeant Pharmaceuticals (NYSE: VRX) following the announced acquisition on Sprout Pharmaceuticals. Sprout recently received FDA approval for Addyi (filbanserin) , a non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD), on August 18th. Valeant will pay ~$1 billion... More